Some
of the common cardiovascular diseases include hypertensive heart
disease, rheumatic heart disease, ischemic heart disease,
inflammatory heart disease, and cerebrovascular heart disease. Major
problems associated with hypertensive heart disease include angina,
hypertrophy, and heart failure. These problems are caused due to high
blood pressure in the heart’s arteries and muscles, which causes
narrowing of arteries and thickening and enlargement of heart. The
global cardiovascular drug market is primarily driven by increase in
prevalence of heart diseases coupled with rising geriatric population
and lifestyle related diseases. In order to cater to this increasing
population suffering from cardiovascular diseases, drugs for
treatment and prevention for these diseases is required. Rising
number of diabetic patients is also expected to be another factor for
growth of the global cardiovascular drugs market. According American
Diabetes Association, in 2015, 30.3 Americans had diabetes, which is
9.4% of the total U.S population.
Download
PDF Brochure of This Business Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1167
Manufacturers
in the market are focusing on mergers and acquisition and new product
launches, which is positively affecting the market growth. However,
stringent drug approval process and side effects of some
cardiovascular drugs hamper growth of the global cardiovascular drugs
market. Moreover, the patent expiry of various blockbuster drugs is
also expected to adversely affect revenue growth of the global
cardiovascular drugs market.
According
to American Heart Association (AHA), in 2013, cardiovascular diseases
accounted for over 17.3 million deaths globally, representing 31% of
all global deaths. The global number is expected to rise to 23.6
million by 2030. In 2010, the global burden of cardiovascular
diseases was US$ 863 billion, and it is expected to rise to US$1044
billion by 2030. Around 2,200 U.S. citizens die due to cardiovascular
diseases, everyday, which is one death in every 40 seconds. Moreover,
coronary heart disease accounts for (45.1%) of the total
cardiovascular disease, followed by stroke (16.5%), high blood
pressure (9.1%), heart failure (8.5%), diseases related to arteries
(3.2%), and other cardiovascular diseases in the U.S.
Cardiovascular
Drugs Market - Competitor Analysis
Some
of the major players operating in the global cardiovascular drugs
market are Pfizer Inc., Bayer AG., Novartis AG., Merck and Co. Inc.,
AstraZeneca Plc, Bristol Myers Squibb Company, Abbott Laboratories,
Sun Pharma Industries, Gilead Sciences Inc., Otsuka Holdings Co.,
Ltd. Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, and
Johnson & Johnson.
Global
Cardiovascular Drugs Market Taxonomy
On
the basis of drug class, the global cardiovascular drugs market is
segmented into:
-
Anti-Hypertensive
-
Anti-Hyperlipidemics
-
Anti-Coagulants
-
Anti-Arrhythmic
-
Anti-Fibrinolytic
-
Others (antianginal drugs, cardiac glycosides, and anti-ischemic drugs)
On
the basis of distribution channels, the global cardiovascular drugs
market is segmented into:
-
Retail Pharmacies
-
Hospital Pharmacies
-
Online Pharmacies
To
know the latest trends and insights prevalent in the cardiovascular
drugs market, click the link below:
https://www.coherentmarketinsights.com/ongoing-insight/cardiovascular-drugs-market-1167
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment